Ferd Private Equity is reported to be in the process of putting Pronova Biocare up for sale. Ferd acquired the pharmaceutical company in Jannuary 2004 for NOK 530m. Artic Securities, the newly established Norwegian ivestment bank, has now valued the company at NOK 15bn. With these valuations, Norwegian press anticipates Ferd to realise a NOK 14bn representing potential historic returns for the Norwegian investor.
Company plans to open offices in New York and Los Angeles, and launch a new SaaS product
Bridges drew equity from its Evergreen fund, which held a final close on £50m in July 2018
Fund targets European companies operating in the consumer, industrial and healthcare services sectors
GP launched a small-cap strategy in Q3 to back companies of the size of ID Systemes